Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Molecular alterations in prostate cancer and association with MRI features

Prostate Cancer and Prostatic Diseases volume 20, pages 430–435 (2017)Cite this article

Subjects

Abstract

Background:

Multiparametric magnetic resonance imaging (mpMRI) has been increasingly used for prostate cancer (PCa). Recent studies identified distinct molecular subclasses of PCa with recurrent genomic alterations. However, the associations between molecular alterations in PCa and characteristics on mpMRI are unknown. Therefore, the objective of this study was to investigate recurrent molecular alterations in PCa and their associations with mpMRI features.

Methods:

Sixty-two PCa nodules >0.5 cm had a preoperative mpMRI. Nodules were evaluated for ERG rearrangement, PTEN deletion, SPINK1 overexpression, SPOP mutation and CHD1 deletion. Each PCa focus was matched to the corresponding location on mpMRI. Lesions were scored by single observer according to the PI-RADSv2 scale.

Results:

Of the 62 nodules, 22 (35.5%) were ERG positive, 6 (9.7%) had SPINK1 overexpression, 6 (9.7%) had SPOP mutations, 4 (6.5%) had CHD1 deletions and 1 (1.6%) had PTEN deletion. All of the nodules with CHD1 deletions were not visible on mpMRI (P=0.037). All of the nodules with SPINK1 overexpression were visible on mpMRI, although the association was not statistically significant (P=0.06). There were no significant associations between any molecular alteration with the severity of the PI-RADS scores (all P>0.05).

Conclusions:

This investigation represents the first description of an association between recurrent molecular alterations and the characterization of PCa nodules on mpMRI. This study can be considered hypothesis-generating for future studies to rigorously evaluate the association of specific PCa molecular subclasses with imaging features and potentially define specific subsets of PCa for which the utility of MRI is higher or lower.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Shariat S, Kattan M, Vickers A, Karakiewicz P, Scardino P . Critical review of prostate cancer predictive tools. Future Oncol 2009; 5: 1555–1584.

    Article  Google Scholar 

  2. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202–1209.

    Article  CAS  Google Scholar 

  3. Resnick MJ, Penson DF . Functional outcomes after treatment for prostate cancer. N Engl J Med 2013; 368: 1654.

    Article  CAS  Google Scholar 

  4. Kaffenberger SD, Barbieri CE . Molecular subtyping of prostate cancer. Curr Opin Urol 2016; 26: 213–218.

    Article  Google Scholar 

  5. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011–1025.

    Article  Google Scholar 

  6. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–243.

    Article  CAS  Google Scholar 

  7. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685–689.

    Article  CAS  Google Scholar 

  8. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.

    Article  CAS  Google Scholar 

  9. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I . Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006; 45: 717–719.

    Article  CAS  Google Scholar 

  10. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006; 8: 465–469.

    Article  CAS  Google Scholar 

  11. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007; 20: 467–473.

    Article  CAS  Google Scholar 

  12. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538–544.

    Article  CAS  Google Scholar 

  13. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882–888.

    Article  Google Scholar 

  14. Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009; 48: 366–380.

    Article  CAS  Google Scholar 

  15. Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol 2014; 66: 851–860.

    Article  CAS  Google Scholar 

  16. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 2013; 63: 347–353.

    Article  CAS  Google Scholar 

  17. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T et al. Multiparametric 3 T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186: 1818–1824.

    Article  Google Scholar 

  18. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313: 390–397.

    Article  CAS  Google Scholar 

  19. Prensner JR, Chinnaiyan AM, Srivastava S . Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 2012; 29: 645–652.

    Article  CAS  Google Scholar 

  20. Srivastava S, Rossi SC . Early detection research program at the NCI. Int J Cancer 1996; 69: 35–37.

    Article  CAS  Google Scholar 

  21. American College of Radiology. MR prostate imaging reporting and data system version 2.0. Available at http://www.acr.org/Quality-Safety/Resources/PIRADS/. Accessed April 2017..

  22. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590–598.

    Article  CAS  Google Scholar 

  23. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214–220.

    Article  CAS  Google Scholar 

  24. Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maille P et al. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer 2015; 121: 1422–1430.

    Article  CAS  Google Scholar 

  25. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451–1460.

    Article  CAS  Google Scholar 

  26. Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Léon P, Roupret M et al. Multiparametric magnetic resonance imaging predicts postoperative pathology but misses aggressive prostate cancers as assessed by cell cycle progression score. J Urol 2015; 194: 1617–1623.

    Article  Google Scholar 

  27. Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL et al. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 2016; 7: 53362–53376.

    Article  Google Scholar 

  28. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519–528.

    Article  CAS  Google Scholar 

  29. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17.

    Article  Google Scholar 

  30. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR et al. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 246–251.

    Article  Google Scholar 

  31. Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ et al. Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn Mol Pathol 2012; 21: 61–68.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by EDRN NCI U01 CA111275-09 (MAR and JMM), NCI R01 CA125612-05A1 and K08CA187417-02), the Prostate Cancer Foundation, and the Urology Care Foundation (Rising Star in Urology Research Award to CEB). CEB is a Damon Runyon Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation. This work was also supported in part by the Translational Research Program at WCM Pathology and Laboratory Medicine.

Author information

Author notes

  1. D Lee and J Fontugne: These authors contributed equally to this work.

  2. J M Mosquera and C E Barbieri: These authors share senior authorship.

Authors and Affiliations

  1. Department of Urology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    D Lee, B D Robinson, A Sboner, M A Rubin, J M Mosquera & C E Barbieri

  2. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    J Fontugne, K Park, T Y MacDonald, B D Robinson, M A Rubin, J M Mosquera & C E Barbieri

  3. Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    J Fontugne, T Y MacDonald, B D Robinson, A Sboner, M A Rubin & J M Mosquera

  4. Department of Radiology, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    N Gumpeni

  5. Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    T Y MacDonald, B D Robinson, A Sboner, M A Rubin, J M Mosquera & C E Barbieri

  6. Department of Computational Biomedicine, Weill Cornell Medicine and New York-Presbyterian, New York, NY, USA

    A Sboner

Authors
  1. D Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Fontugne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Gumpeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Y MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B D Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Sboner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M A Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J M Mosquera
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C E Barbieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to J M Mosquera or C E Barbieri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, D., Fontugne, J., Gumpeni, N. et al. Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis 20, 430–435 (2017). https://doi.org/10.1038/pcan.2017.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2017.33

This article is cited by

Search

Advanced search

Quick links